Pete has both advised a number of biotech, small and medium pharma companies and provided due diligence assessments for venture capital companies since leaving GSK end December 2003. When performing these roles he has drawn on extensive experience of reviewing individual project plans, identifying the issues and threats to project viability before shaping strategies and tactics to maximize the commercial potential of development assets. More recently he has co-founded Theradeas Ltd